EGFR and non-small cell lung carcinoma: (150) (n = 90 and 71 EGFR-mutant NSCLC patients, respectively) found that PD-L1 expression was significantly associated with shorter PFS for EGFR-mutant NSCLC patients treated with EGFR-TKIs.